RxDoctor Payments DataLook up a doctor →

Andrew Davis, MD

Medical Oncology · Florissant, MONPI 1417374604

Payments from drug & device makers

$1,196,792in general payments, 2019–2025

Across 197 payments — averaging $6075.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$427K
  • AstraZeneca$351K
  • E.r. Squibb & Sons, L.L.C.$212K
  • Immunogen, Inc.$106K
  • Merck$35K
  • Genentech, Inc.$33K
  • plus $32K from 6 others

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie170$427,340
AstraZeneca6$351,002
E.r. Squibb & Sons, L.L.C.3$211,546
Immunogen, Inc.4$106,406
Merck3$34,886
Genentech, Inc.2$33,205
Pfizer3$11,365
GSK2$10,634
Puma Biotechnology, Inc.1$10,248
Exelixis Inc.1$121
Lilly USA, LLC1$21
EMD Serono, Inc.1$18

How this compares

$1,196,792 in reported general payments places this provider in the 70th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$517,717
Medicare patients
209
Services billed
20,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Florissant

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →